Archive · 25 Jul 2025
Cipla CEO: US Tariffs Impact Expected, Not 'Debilitating'
The head of Cipla, a big drug company, talked about potential US tariffs on medicines.
He said the tariffs, or extra taxes on imported goods, would affect the company but wouldn't cause major problems.
Cipla had a good financial quarter, with increased sales and profits.
The CEO thinks any tariffs on medicines will be lower than the average tax rate on other products.
He also mentioned the company's plans to grow in important markets and develop new medicines.
Cipla's CEO says US tariffs will impact, but not 'debilitate' the pharma industry.
Cipla's Q1 revenue was ₹6,957 crore, up 4% year-over-year.
Profit after tax for Q1 was ₹1,298 crore, up 10% year-over-year.
The CEO believes tariffs on pharma will be lower than the average 15% for most countries.
Focus areas include growing key markets and investing in the future pipeline.
- Who
- Umang Vohra, Cipla's MD and Global CEO
- What
- Cipla's CEO discusses the potential impact of US tariffs on the pharmaceutical industry and reports on the company's Q1 financial performance.
- When
- Q1 of 2025, ending June 30, with article published July 25, 2025
- Where
- The US, where potential tariffs are discussed, and various markets where Cipla operates.
- Why
- To address concerns about US tariffs and report on the company's financial results.
Potential Impact
Mitigated Concerns
Impact Severity
Potential Impact
Industry representatives anticipate an impact due to tariffs on pharmaceutical products.
Mitigated Concerns
Cipla's CEO believes the impact will not be severe enough to cripple the business, suggesting lower tariff rates than average.
- Company
- Cipla Ltd
- Q1 Revenue (₹)
- 6,957 crore
- Q1 Profit After Tax (₹)
- 1,298 crore
- Revenue Growth (YoY)
- 4%
- Profit Growth (YoY)
- 10%
- US Business Revenue
- $226 million